Moderna filed its opposition letter Monday in the US District Court for the District of Delaware, responding to a May 16 letter from Arbutus and its co-plaintiff, Genevant Sciences GmbH.
“Plaintiffs are unabashedly making different factual representations under the guise of ‘reconsideration’ so that their case is not similarly limited,” Moderna wrote, accusing Arbutus and Genevant of reversing course ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.